Stomatology ›› 2023, Vol. 43 ›› Issue (9): 854-860.doi: 10.13591/j.cnki.kqyx.2023.09.016
• Summary • Previous Articles Next Articles
Revised:
2023-03-18
Online:
2023-09-28
Published:
2023-09-28
CLC Number:
ZHOU Hangfan, JIANG Lu. Viral infection-related pemphigus[J]. Stomatology, 2023, 43(9): 854-860.
[1] |
Egami S, Yamagami J, Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid[J]. J Allergy ClinImmunol, 2020, 145(4):1031-1047.
doi: 10.1016/j.jaci.2020.02.013 |
[2] | Pollmann R, Schmidt T, Eming R, et al. Pemphigus:A comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches[J]. Clinic Rev AllergImmunol, 2018, 54(1):1-25. |
[3] |
Kridin K. Pemphigus group:Overview, epidemiology, mortality, and comorbidities[J]. Immunol Res, 2018, 66(2):255-270.
doi: 10.1007/s12026-018-8986-7 |
[4] | Di Lernia V, Casanova DM, Goldust M, et al. Pemphigus vulgaris and bullous pemphigoid:Update on diagnosis and treatment[J]. Dermatol Pract Concept, 2020, 10(3):e2020050. |
[5] |
Siddig O, Mustafa MB, Kordofani Y, et al. The epidemiology of autoimmune bullous diseases in Sudan between 2000 and 2016[J]. PLoS One, 2021, 16(7):e0254634.
doi: 10.1371/journal.pone.0254634 |
[6] |
Didona D, Maglie R, Eming R, et al. Pemphigus:Current and future therapeutic strategies[J]. Front Immunol, 2019, 10:1418.
doi: 10.3389/fimmu.2019.01418 pmid: 31293582 |
[7] |
Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and Pemphigus foliaceus:Differences in epidemiology and mortality[J]. Acta Derm Venereol, 2017, 97(9):1095-1099.
doi: 10.2340/00015555-2706 |
[8] |
Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris[J]. An Bras Dermatol, 2019, 94(3):264-278.
doi: S0365-05962019000300264 pmid: 31365654 |
[9] |
Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus[J]. Nat Rev Dis Primers, 2017, 3:17026.
doi: 10.1038/nrdp.2017.26 pmid: 28492232 |
[10] |
Ghaedi F, Etesami I, Aryanian Z, et al. Drug-induced pemphigus: A systematic review of 170 patients[J]. Int Immunopharmacol, 2021, 92:107299.
doi: 10.1016/j.intimp.2020.107299 |
[11] |
Kurata M, Mizukawa Y, Aoyama Y, et al. Herpes simplex virus reactivation as a trigger of mucous lesions in pemphigus vulgaris[J]. Br J Dermatol, 2014, 171(3):554-560.
doi: 10.1111/bjd.12961 pmid: 24660994 |
[12] |
Kridin K, Zelber-Sagi S, Comaneshter D, et al. Is there an association between pemphigus and hepatitis viruses? A population-based large-scale study[J]. Immunol Res, 2017, 65(5):1083-1088.
doi: 10.1007/s12026-017-8950-y pmid: 28905194 |
[13] |
Horiguchi Y, Fujii S, Takase S, et al. Case of pemphigus vulgaris in oral mucosa showing an extension to the body surface with recurrent varicella[J]. Int J Dermatol, 2005, 44(11):951-954.
pmid: 16336532 |
[14] |
Murata T, Morita K. Unsuspected varicella-zoster infection complicating mucosal-dominant pemphigus vulgaris[J]. Int J Dermatol, 2013, 52(11):1453-1454.
doi: 10.1111/j.1365-4632.2011.05393.x pmid: 23879518 |
[15] |
Oliveira-Batista DP, Janini MER, Fernandes NC, et al. Laboratory diagnosis of herpesvirus infections in patients with Pemphigus vulgaris lesions[J]. Intervirology, 2013, 56(4):231-236.
doi: 10.1159/000349889 pmid: 23735576 |
[16] |
Meibodi NT, Nahidi Y, Mahmoudi M, et al. Evaluation of coexistence of the Human Herpesvirus type 8 (HHV-8) infection and pemphigus[J]. Int J Dermatol, 2010, 49(7):780-783.
doi: 10.1111/j.1365-4632.2009.04398.x pmid: 20618497 |
[17] |
Markitziu A, Pisanty S. Pemphigus vulgaris after infection by Epstein-Barr virus[J]. Int J Dermatol, 1993, 32(12):917-918.
pmid: 8125704 |
[18] |
Singh A, Bharadwaj SJ, Chirayath AG, et al. Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature[J]. J Cosmet Dermatol, 2022, 21(6):2311-2314.
doi: 10.1111/jocd.v21.6 |
[19] |
Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirusentry[J]. Nat Rev Microbiol, 2021, 19(2):110-121.
doi: 10.1038/s41579-020-00448-w pmid: 33087881 |
[20] |
Zhu SY, Viejo-Borbolla A. Pathogenesis and virulence of Herpes simplexvirus[J]. Virulence, 2021, 12(1):2670-2702.
doi: 10.1080/21505594.2021.1982373 |
[21] |
Krain LS. Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955-1973[J]. Arch Dermatol, 1974, 110(6):862-865.
doi: 10.1001/archderm.110.6.862 pmid: 4613278 |
[22] |
Schlüpen EM, Wollenberg A, Hänel S, et al. Detection of Herpes simplex virus in exacerbated Pemphigus vulgaris by polymerase chain reaction[J]. Dermatology, 1996, 192(4):312-316.
pmid: 8864363 |
[23] |
Tufano MA, Baroni A, Buommino E, et al. Detection of herpesvirus DNA in peripheral blood mononuclear cells and skin lesions of patients with pemphigus by polymerase chain reaction[J]. Br J Dermatol, 1999, 141(6):1033-1039.
doi: 10.1046/j.1365-2133.1999.03201.x |
[24] |
Machado ARDSR, La Serra L, Turatti A, et al. Herpes simplex virus 1 and cytomegalovirus are associated with Pemphigus vulgaris but not with Pemphigus foliaceus disease[J]. Exp Dermatol, 2017, 26(10):966-968.
doi: 10.1111/exd.2017.26.issue-10 |
[25] |
Ruocco V, Wolf R, Ruocco E, et al. Viruses in pemphigus:A casual or causal relationship?[J]. Int J Dermatol, 1996, 35(11):782-784.
pmid: 8915728 |
[26] |
Gye J, Nam CH, Kim JS, et al. Pemphigus vulgaris in pregnancy associated with herpes virus type 1 infection[J]. Ann Dermatol, 2014, 26(2):258-260.
doi: 10.5021/ad.2014.26.2.258 |
[27] |
Pranteda G, Carlesimo M, Bottoni U, et al. Pemphigus vulgaris in a patient with arthritis and uveitis:Successful treatment with immunosuppressive therapy and acyclovir[J]. Dermatol Ther, 2014, 27(4):215-218.
doi: 10.1111/dth.12120 pmid: 24548566 |
[28] |
Esmaili N, Hallaji Z, Abedini R, et al. Pemphigus vulgaris and herpesviruses:Is there any relationship?[J]. Int J Dermatol, 2010, 49(11):1261-1265.
doi: 10.1111/ijd.2010.49.issue-11 |
[29] |
Mohammadi F, Khalili Z, Marashi SM, et al. The potential roles of herpesvirus and cytomegalovirus in the exacerbation of Pemphigus vulgaris[J]. Dermatol Pract Concept, 2018, 8(4):262-271.
doi: 10.5826/dpc.0804a03 pmid: 30479853 |
[30] |
Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4:18017.
doi: 10.1038/nrdp.2018.17 pmid: 29644994 |
[31] |
Rodríguez Y, Vatti N, Ramírez-Santana C, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease[J]. J Autoimmun, 2019, 102:8-37.
doi: S0896-8411(19)30043-5 pmid: 31072742 |
[32] |
Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis[J]. World J Gastroenterol, 2021, 27(1):19-36.
doi: 10.3748/wjg.v27.i1.19 |
[33] |
Berkun Y, Mimouni D, Shoenfeld Y. Pemphigus following hepatitis B vaccination:Coincidence or causality?[J]. Autoimmunity, 2005, 38(2):117-119.
doi: 10.1080/08916930400027078 |
[34] |
Ujiie I, Ujiie H, Yoshimoto N, et al. Prevalence of infectious diseases in patients with autoimmune blistering diseases[J]. J Dermatol, 2020, 47(4):378-384.
doi: 10.1111/jde.v47.4 |
[35] |
Agmon-Levin N, Ram M, Barzilai O, et al. Prevalence of hepatitis C serum antibody in autoimmune diseases[J]. J Autoimmun, 2009, 32(3/4):261-266.
doi: 10.1016/j.jaut.2009.02.017 |
[36] |
Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature[J]. Autoimmun Rev, 2011, 10(9):527-535.
doi: 10.1016/j.autrev.2011.04.003 pmid: 21527361 |
[37] |
Demirci GT, Aydingoz IE, Mansur AT, et al. Hepatitis C and hepatitis B virus infections in the etiopathogenesis of pemphigus[J]. An Bras Dermatol, 2014, 89(3):423-426.
doi: S0365-05962014000300423 pmid: 24937815 |
[38] |
Wang GQ, Xu HH, Wang YK, et al. Higher prevalence of human herpesvirus 8 DNA sequence and specific IgG antibodies in patients with pemphigus in China[J]. J Am Acad Dermatol, 2005, 52(3):460-467.
doi: 10.1016/j.jaad.2004.10.882 |
[39] |
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19(3):141-154.
doi: 10.1038/s41579-020-00459-7 pmid: 33024307 |
[40] |
Solimani F, Mansour Y, Didona D, et al. Development of severe Pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2[J]. J Eur Acad Dermatol Venereol, 2021, 35(10):e649-e651.
doi: 10.1111/jdv.17480 pmid: 34169588 |
[41] |
Thongprasom K, Pengpis N, Phattarataratip E, et al. Oral pemphigus after COVID-19 vaccination[J]. Oral Dis, 2022, 28(Suppl 2):2597-2598.
doi: 10.1111/odi.v28.S2 |
[42] |
Koutlas IG, Camara R, Argyris PP, et al. Development of Pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine[J]. Oral Dis, 2022, 28(Suppl 2):2612-2613.
doi: 10.1111/odi.v28.S2 |
[43] |
Calabria E, Canfora F, Mascolo M, et al. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination:A Case report of Pemphigus Vulgaris and a literature review[J]. Pathol Res Pract, 2022, 232:153834.
doi: 10.1016/j.prp.2022.153834 |
[44] | Knechtl GV, SeyedJafari SM, Berger T, et al. Development of Pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient[J]. J Eur Acad Dermatol Venereol, 2022, 36(4):e251-e253. |
[45] | Almasi-Nasrabadi M, Ayyalaraju RS, Sharma A, et al. New onset Pemphigus foliaceus following AstraZeneca COVID-19 vaccination[J]. J Eur Acad Dermatol Venereol, 2023, 37(1):e1-e3. |
[46] |
De Medeiros VLS, Monteiro-Neto AU, França DDT, et al. Pemphigus vulgaris after COVID-19:A case of induced autoimmunity[J]. SN Compr Clin Med, 2021, 3(8):1768-1772.
doi: 10.1007/s42399-021-00971-8 |
[47] |
Ruocco E, Ruocco V, Schiavo AL, et al. Viruses and pemphigus:An intriguing never-ending story[J]. Dermatology, 2014, 229(4):310-315.
doi: 10.1159/000365845 |
[48] |
Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases[J]. Crit Rev Microbiol, 2019, 45(4):394-412.
doi: 10.1080/1040841X.2019.1614904 pmid: 31145640 |
[49] |
Rojas M, Restrepo-Jiménez P, Monsalve DM, et al. Molecular mimicry and autoimmunity[J]. J Autoimmun, 2018, 95:100-123.
doi: S0896-8411(18)30536-5 pmid: 30509385 |
[50] |
Rose NR. Negative selection, epitope mimicry and autoimmunity[J]. Curr Opin Immunol, 2017, 49:51-55.
doi: S0952-7915(17)30133-4 pmid: 29102863 |
[51] |
Zhao ZS, Granucci F, Yeh L, et al. Molecular mimicry by Herpes simplex virus-type 1:Autoimmune disease after viral infection[J]. Science, 1998, 279(5355):1344-1347.
pmid: 9478893 |
[52] |
Jog NR, James JA. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus[J]. Front Immunol, 2021, 11:623944.
doi: 10.3389/fimmu.2020.623944 |
[53] |
Li N, Aoki V, Liu Z, et al. From insect bites to a skin autoimmune disease:A conceivable pathway to endemic Pemphigus foliaceus[J]. Front Immunol, 2022, 13:907424.
doi: 10.3389/fimmu.2022.907424 |
[54] |
Ishii N. Significance of anti-desmocollin autoantibodies in pemphigus[J]. J Dermatol, 2023, 50(2):132-139.
doi: 10.1111/jde.v50.2 |
[55] |
Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with Pemphigus vulgaris[J]. Front Immunol, 2018, 9:1190.
doi: 10.3389/fimmu.2018.01190 pmid: 29915578 |
[56] |
Schwimmbeck PL, Dyrberg T, Drachman DB, et al. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with Herpes simplexvirus[J]. J Clin Invest, 1989, 84(4):1174-1180.
doi: 10.1172/JCI114282 pmid: 2551924 |
[57] |
Ahmed AR, Moy RL, Chia D, et al. Immune complexes in pemphigus and bullous pemphigoid[J]. Dermatologica, 1983, 166(4):175-180.
pmid: 6343146 |
[58] |
Aoyama Y, Nagai M, Kitajima Y. Binding of pemphigus vulgaris IgG to antigens in desmosome core domains excludes immune complexes rather than directly splitting desmosomes[J]. Br J Dermatol, 2010, 162(5):1049-1055.
doi: 10.1111/j.1365-2133.2010.09672.x pmid: 20222919 |
[59] | Tomer Y, Villanueva R. Infection and autoimmune thyroid diseases[M]//Infection and Autoimmunity. Amsterdam:Elsevier, 2004:515-530. |
[60] | Aibara N, Ohyama K. Revisiting immune complexes:Key to understanding immune-related diseases[J]. Adv Clin Chem, 2020, 96:1-17. |
[61] |
Cooksley H, Riva A, Katzarov K, et al. Differential expression of immune inhibitory checkpoint signatures on antiviral and inflammatory T cell populations in chronic hepatitis B[J]. J Interferon Cytokine Res, 2018, 38(7):273-282.
doi: 10.1089/jir.2017.0109 |
[62] |
Dong YJ, Li XF, Zhang L, et al. CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B[J]. BMC Immunol, 2019, 20(1):27.
doi: 10.1186/s12865-019-0309-9 |
[63] |
Jubel JM, Barbati ZR, Burger C, et al. The role of PD-1 in acute and chronic infection[J]. Front Immunol, 2020, 11:487.
doi: 10.3389/fimmu.2020.00487 pmid: 32265932 |
[64] |
Wang JY, Li C, Fu JJ, et al. Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B[J]. Scand J Immunol, 2019, 89(5):e12755.
doi: 10.1111/sji.2019.89.issue-5 |
[65] |
Tavakolpour S, Mahmoudi H, Mirzazadeh A, et al. Pathogenic and protective roles of cytokines in pemphigus:A systematic review[J]. Cytokine, 2020, 129:155026.
doi: 10.1016/j.cyto.2020.155026 |
[66] |
Sugiyama H, Matsue H, Nagasaka A, et al. CD4+CD25high regulatory T cells are markedly decreased in blood of patients with Pemphigus vulgaris[J]. Dermatology, 2007, 214(3):210-220.
pmid: 17377382 |
[67] |
Su W, Zhou Q, Ke Y, et al. Functional inhibition of regulatory CD4+CD25+T cells in peripheral blood of patients with Pemphigus vulgaris[J]. Clin Exp Dermatol, 2020, 45(8):1019-1026.
doi: 10.1111/ced.v45.8 |
[68] |
Veldman C, Höhne A, Dieckmann D, et al. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with Pemphigus vulgaris[J]. J Immunol, 2004, 172(10):6468-6475.
doi: 10.4049/jimmunol.172.10.6468 |
[69] | Timoteo RP, da Silva MV, Miguel CB, et al. Th1/Th17-related cytokines and chemokines and their implications in the pathogenesis of Pemphigus vulgaris[J]. Mediators Inflamm, 2017, 2017:7151285. |
[70] |
Liu TM, Li S, Ying SN, et al. The IL-23/IL-17 pathway in inflammatory skin diseases:From bench to bedside[J]. Front Immunol, 2020, 11:594735.
doi: 10.3389/fimmu.2020.594735 |
[71] |
Grunwald MH, Katz I, Friedman-Birnbaum R. Association of pemphigus vulgaris and herpes simplex virus infection[J]. Int J Dermatol, 1986, 25(6):392-393.
pmid: 3759316 |
[72] | Fernandes NC, Rampinelli H, Souza LM, et al. Refractory pemphigus foliaceus associated with herpesvirus infection:case report[J]. Rev Inst Med Trop Sao Paulo, 2017, 59:e41. |
[73] |
Chiu HY, Chang CY, Hsiao CH, et al. Concurrent cytomegalov-irus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone[J]. Acta Derm Venereol, 2013, 93(2):200-201.
doi: 10.2340/00015555-1429 |
[74] |
Baum S, Atar I, Coster D, et al. Relationship between Pemphigus Vulgaris severity and PCR-positive Herpes simplex virus[J]. Acta Derm Venereol, 2022, 102:adv00703.
doi: 10.2340/actadv.v102.917 |
[75] |
Konda D, Chandrashekar L, Dhodapkar R, et al. Clinical markers of Herpes simplex virus infection in patients with pemphigus vulgaris[J]. J Am Acad Dermatol, 2023, 88(3):587-592.
doi: 10.1016/j.jaad.2019.06.002 |
[76] |
Brandão MLFB, Fernandes NC, Batista DP, et al. Refractory Pemphigus vulgaris associated with herpes infection:Case report and review[J]. Rev Inst Med Trop Sao Paulo, 2011, 53(2):113-117.
doi: 10.1590/S0036-46652011000200010 |
[77] |
Zhong ZY, Liao WT, Dai LY, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection[J]. Ann Rheum Dis, 2022, 81(4):584-591.
doi: 10.1136/annrheumdis-2021-221650 |
[78] |
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies:Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6):1297-1309.
doi: S0016-5085(17)30173-7 pmid: 28219691 |
[79] |
Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with Pemphigus vulgaris and demonstrates a steroid-sparing effect[J]. Br J Dermatol, 2020, 182(5):1111-1119.
doi: 10.1111/bjd.18482 pmid: 31487383 |
[80] |
Frampton JE. Rituximab:A review in Pemphigus vulgaris[J]. Am J Clin Dermatol, 2020, 21(1):149-156.
doi: 10.1007/s40257-019-00497-9 pmid: 31838645 |
[81] |
Kusumoto S, Arcaini L, Hong XN, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy[J]. Blood, 2019, 133(2):137-146.
doi: 10.1182/blood-2018-04-848044 pmid: 30341058 |
[82] |
Smalls DJ, Kiger RE, Norris LB, et al. Hepatitis B virus reactivation:Risk factors and current management strategies[J]. Pharmacotherapy, 2019, 39(12):1190-1203.
doi: 10.1002/phar.v39.12 |
[1] | ZHANG Mengjie, CHEN Minjie. Temporomandibular disorders in patients with autoimmune diseases:Clinical analysis of 15 cases and literature review [J]. Stomatology, 2022, 42(11): 1019-1025. |
[2] | . Drug-induced pemphigus [J]. , 2016, 36(9): 769-773. |
[3] | Li-Qun YANG. Research progress ofthe clinical diagnosis and treatment of pemphigus [J]. , 2016, 36(9): 852-856. |
[4] | You WU. Research progress of paraneoplastic pemphigus [J]. , 2016, 36(7): 645-648. |
[5] | . Epidemiological survey on oral health status of patients with rheumatoid immune disease [J]. , 2016, 36(3): 248-252. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||